Pharmaceuticals

GLORIA PHARMA.

GLORIA PHARMA. released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 539.11 M, actual EPS CNY 0.0425

GLORIA PHARMA to Release FY2026 Q1 Earnings Report on April 28 After-Market BJT

GLORIA PHARMA. to Release FY2025 Earnings on April 28 After-Market (BJT), Forecast Revenue CNY 2.364 B, EPS CNY 0.11

GLORIA PHARMA. released FY2025 Q4 earnings on April 14 After-Market BJT, actual revenue CNY 470.45 M, actual EPS CNY 0.0608

GLORIA PHARMA. released FY2025 earnings on April 14 After-Market BJT, actual revenue CNY 2.135 B (forecast CNY 2.364 B), actual EPS CNY 0.1686 (forecast CNY 0.11)

GLORIA PHARMA. released FY2025 Q3 earnings on October 28 During-Market (BJT), actual revenue CNY 565.5 M, actual EPS CNY 0.0487

GLORIA PHARMA. released FY2025 9 Months Earnings on October 28 During-Market (BJT), actual revenue CNY 1.665 B, actual EPS CNY 0.1084

GLORIA PHARMA. FY2025 Q3 Earnings Release on October 29 During-Market BJT

GLORIA PHARMA. released FY2025 Q2 earnings on August 26 After-Market (BJT), actual revenue CNY 548.25 M, actual EPS CNY 0.033

GLORIA PHARMA. released FY2025 Semi-Annual Earnings on August 26 After-Market BJT, actual revenue CNY 1.1 B, actual EPS CNY 0.0596

GLORIA PHARMA. FY2025 Semi-Annual Earning Release on August 27, 2025 (BJT)

Yuheng Pharmaceutical Responds to Investor Queries on V12 Cooperation Model and Market Performance

Pemabete Expected to Be Available in Domestic Market After September This Year

Yuheng Pharmaceutical Executives' Share Reduction Plan Completed

Pude Pharmaceutical's Injection of Multiple Vitamins Passes Consistency Evaluation

Yuheng Pharmaceutical and Sicc Electronics Release Company Survey Records

Yuheng Pharmaceutical Accepts Institutional Research and Explains Business Conditions

Yuhan Pharmaceutical's Wholly-Owned Subsidiary Signs Promotional Agreement with Eisai

Yuheng Pharmaceutical Signs Promotion Agreement for Peibambeite with Xinghe Pharmaceutical

Yuheng Pharmaceutical Executives Plan to Reduce Shares

002437

GLORIA PHARMA plans to resolve the equity transfer debt dispute with Qingdao Pusheng Puli by signing an agreement, involving a transfer payment of 117.6 million yuan for a 42.12% equity stake in Guangzhou GLORIA. Pusheng Puli has failed to make timely payments and has been sued in court. Pusheng Puli will transfer its 20.64% equity stake to Youpeng Biotechnology to repay the debt. In addition, New Times' "New Times Convertible Bonds" will stop conversion on November 4, and unconverted bonds will be forcibly redeemed, which may result in losses for investors

Zhitong

Midday announcement: GLORIA PHARMA plans to sign an agreement to resolve the debt dispute related to the equity transfer of GLORIA BIO

GLORIA PHARMA announced that it will resolve the debt dispute regarding the equity transfer payment with Pusheng Puli through an agreement. Pusheng Puli intends to transfer its 20.64% equity stake in GLORIA PHARMA to Youpeng Bio, and the proceeds will be used to repay debts owed to the company. The lawsuit regarding this equity transfer has entered the enforcement stage, and the subsequent process is complex and uncertain

GLORIA PHARMA: Puxing Puli plans to transfer 20.64% equity of GLORIA PHARMA to repay the debts owed by Puxing Puli to the company

GLORIA PHARMA provides a bank credit guarantee of 40 million yuan for its wholly-owned subsidiaries, Guangzhou Yudong Health Pharmaceutical Co., Ltd. and Harbin Leibotong Pharmaceutical Co., Ltd. This guarantee includes a credit of 30 million yuan for Yudong Pharmaceutical and 10 million yuan for Leibotong, with the total guarantee amount accounting for 2.06% of the audited net assets attributable to shareholders of the listed company for 2024. As of June 30, 2025, the assets and net assets of Yudong Pharmaceutical and Leibotong were 354.2715 million yuan, 306.2614 million yuan and 102.2375 million yuan, 39.9349 million yuan, respectively, with no overdue guarantee risk

GLORIA PHARMA: Provides guarantees for 40 million bank credit for two wholly-owned subsidiaries

GLORIA PHARMA announced that in the first half of 2025, the company achieved operating revenue of 1.1 billion yuan, a year-on-year decrease of 9.97%; the net profit attributable to shareholders of the listed company was 134 million yuan, a year-on-year increase of 7.56%; basic earnings per share were 0.0613 yuan/share, a year-on-year increase of 10.25%

GLORIA PHARMA: Net profit in the first half of 2025 increased by 7.56% year-on-year

GLORIA PHARMA announced that its wholly-owned subsidiary, Pude Pharmaceutical, has received the Drug Supplement Application Approval Notice issued by the National Medical Products Administration for injectable multivitamins. This drug has passed the consistency evaluation of the quality and efficacy of generic drugs. Injectable multivitamins are suitable for adult patients and children over 11 years old, with sales expected to reach RMB 1.916 billion in urban public hospitals and county-level public medical institutions in China in 2024. Pude Pharmaceutical has invested approximately RMB 3.6706 million in the consistency evaluation work for this drug

GLORIA PHARMA: Injectable multiple vitamins pass consistency evaluation

GLORIA PHARMA's wholly-owned subsidiary Tianjin GLORIA Boda Technology Co., Ltd. has signed a marketing service agreement with Eisai (China) Pharmaceutical Co., Ltd., authorizing Tianjin Boda to exclusively promote Mecobalamin Injection (brand name: Micope). The agreement is valid until March 31, 2026, and both parties can negotiate a renewal. This move will enrich the company's product line, is expected to increase operating revenue and profit, and enhance professional academic promotion capabilities

GLORIA PHARMA's subsidiary signed a marketing service agreement with Eisai China Pharmaceutical for Mecobalamin Injection

According to the Zhitong Finance APP, GLORIA PHARMA announced that on May 29, 2025, the company received a "Share Reduction Plan Notification Letter" issued by Mr. Li Runbao, Vice President, Mr. Wang Xiaohang, Vice President, and Ms. Liu Yueyin, Director, Vice President, and Board Secretary, stating that the aforementioned individuals plan to reduce their holdings by a total of no more than 1.4346 million shares

Some directors and executives of GLORIA PHARMA plan to reduce their holdings by a total of no more than 1.4346 million shares

GLORIA PHARMA announced that Vice General Manager Li Runbao, Vice General Manager Wang Xiaohang, and Director, Vice General Manager, and Board Secretary Liu Yueyin plan to reduce their holdings in the company through centralized bidding within three months after 15 trading days from the date of the announcement. Li Runbao and Wang Xiaohang each plan to reduce their holdings by 587,500 shares, accounting for 0.0262% of the company's total share capital; Liu Yueyin plans to reduce his holdings by 259,600 shares, accounting for 0.0116% of the company's total share capital. The reason for the reduction is personal funding needs, and the reduction price will be determined at market price

GLORIA PHARMA: Three senior executives plan to collectively reduce their holdings by 0.0639% of the company's shares

002907

Pharmaceutical stocks surged, with Pharscin Pharma and GLORIA PHARMA hitting the limit up, while Weikang Pharmaceutical, Haixiang Pharmaceutical, Yipinhong, and Panlong Pharmaceutical also rose

Pharscin Pharma

WECOME

HISOAR

ApicHope

Panlong Pharmaceutical

Pharmaceutical stocks surge, Pharscin Pharma and GLORIA PHARMA hit the limit up

GLORIA PHARMA and Xinghe Pharmaceutical signed a "Joint Promotion Agreement" to jointly promote Pemafibrate Tablets (brand name: Pailongda), with the agreement taking effect on June 1, 2025. Pemafibrate Tablets are the world's first novel highly selective PPARα modulator, aimed at reducing plasma triglyceride levels and increasing high-density lipoprotein cholesterol levels. This collaboration will enrich GLORIA PHARMA's product pipeline, is expected to increase revenue and profits, and enhance competitiveness in the cardiovascular field

GLORIA PHARMA. and Xinghe Pharmaceutical signed a joint promotion agreement for Pemabertinib tablets

GLORIA PHARMA.(002437.SZ)